Xencor Revenue and Competitors
Estimated Revenue & Valuation
- Xencor's estimated annual revenue is currently $77.3M per year.
- Xencor received $Undisclosed in venture funding in March 2018.
- Xencor's estimated revenue per employee is $217,000
- Xencor's total funding is $133.4M.
Employee Data
- Xencor has 356 Employees.
- Xencor grew their employee count by 3% last year.
Xencor's People
Name | Title | Email/Phone |
---|---|---|
1 | SVP, Chief Financial Officer | Reveal Email/Phone |
2 | SVP, Clinical Development and Medical Affairs | Reveal Email/Phone |
3 | VP, Biometrics | Reveal Email/Phone |
4 | VP, CMC Operations | Reveal Email/Phone |
5 | VP, Finance | Reveal Email/Phone |
6 | Head Statistical Programming | Reveal Email/Phone |
7 | VP, Nonclinical & Bioanalytical Development | Reveal Email/Phone |
8 | VP, Development Sciences, Head Protein Sciences & Technology | Reveal Email/Phone |
9 | Head, Corporate Communications and Investor Relations | Reveal Email/Phone |
10 | VP Translational Biology | Reveal Email/Phone |
Xencor Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Xencor?
Antibodies by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics antibodies that target new biological mechanisms and are more potent, safer and longer lasting to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power$133.4M
Total Funding
356
Number of Employees
$77.3M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Xencor News
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer...
Several equities analysts recently issued reports on XNCR shares. BMO Capital Markets started coverage on Xencor in a research report on Friday,...
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer...
Xencor Reports Second Quarter 2021 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--August 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatm ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $138.7M | 411 | 35% | N/A |
#2 | N/A | 418 | 42% | N/A |
#3 | $98.3M | 437 | 3% | N/A |
#4 | N/A | 586 | 1% | N/A |
#5 | $153.1M | 630 | 6% | N/A |
Xencor Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2005-10-19 | $20.0M | D | Zen Investments LLC | Article |
2006-07-12 | $6.0M | Undisclosed | Novo Nordisk | Article |
2006-10-20 | $45.0M | Undisclosed | MedImmune Ventures Inc | Article |
2007-10-26 | $15.0M | E | RBC Capital Markets | Article |
2013-12-04 | $80.5M | Undisclosed | Credit Suisse Securities (USA) LLC | Article |
2015-03-03 | $122.9M | Undisclosed | Leerink Partners | Article |
2016-12-02 | $126.5M | Undisclosed | Leerink Partners | Article |
2018-03-20 | $Undisclosed | Undisclosed | Leerink Partners | Article |